Adding chemoembolization for stable stage IV lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding a procedure called bronchial artery chemoembolization (delivering chemotherapy directly to the tumor's blood supply) to your usual care can help control lung cancer that has stabilized after first-line chemotherapy and immunotherapy. The goal is to see if it improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called squamous cell carcinoma, confirmed by a biopsy.
- Your cancer is stage IV, meaning it has spread beyond the lungs.
- You have already had 4 to 6 cycles of standard first-line chemotherapy plus immunotherapy, and your cancer has either shrunk or stayed stable.
- You are between 18 and 80 years old.
- You are physically active enough to care for yourself (ECOG score 0-1).
- You do not have certain genetic mutations (EGFR or ALK) that are typically treated with targeted therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding radiotherapy to immunotherapy and chemotherapy can help people whose lung cancer has spread to the liver and who have already tried standard treatments. It aims to see if this combination is safe and works better at shrinking tumors.
This trial tests whether giving a combination of two immunotherapy drugs with chemotherapy before surgery can help shrink stage III lung cancer and improve outcomes. It is for people whose cancer has spread to lymph nodes in the chest but can still be removed with surgery.
This trial tests whether adding an immunotherapy medicine to standard chemotherapy after surgery can improve outcomes for some people with non-small cell lung cancer. It may help by boosting the immune system to reduce the chance the cancer comes back.
This trial tests a new combination of immunotherapy and chemotherapy before and after standard chemoradiation for patients with stage III lung cancer that cannot be surgically removed. The goal is to see if this approach improves outcomes compared to chemoradiation alone.
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
This trial tests a new combination of an immunotherapy drug (IBI363) plus chemotherapy before surgery in people with Stage III lung cancer that can't be removed at first. The goal is to shrink the tumor so it can be surgically removed.
Hear when a new Lung Squamous Cell Carcinoma Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.